1. Please supply me with your most up to date wound care formulary (please indicate if you do not work from a formulary)?

This information is available at http://www.birminghamandsurroundsformulary.nhs.uk/  We are therefore withholding this information under Section 21 of the Freedom of Information                 Act 2000 “information already accessible “.

2. Who has operational responsibility for the formulary including the addition or deletion of products?

BSSE Area Prescribing Committee, advised by Wound Care group

3. Please provide information on how compliance with your formulary is enforced?

Pharmacies keep a small range of dressings namely those containing antibiotics and antiseptics and some interactive dressings. If the dressing is on the formulary it will be included on the pharmacy system.  If a dressing is not on the formulary, then it cannot be provided.

The wound care committee (a sub-group of the Area Prescribing Committee) has harmonised all the dressings across the Birmingham & surrounds to produce one formulary. New products will be evaluated using a standard evaluation form in at least 2 trusts by the TVNs/DN & then any recommendations are then approved at the APC.

Please see attachment 1 Attachment 1

4. Please provide information on how products are evaluated prior to being accepted onto the formulary? If this is part of a clinical evaluation or clinical trial, please provide the results.

The wound care committee (a sub-group of the Area Prescribing Committee) has harmonised all the dressings across the Birmingham & surrounds to produce one formulary. New products will be evaluated using a standard evaluation form in at least 2 trusts by the TVNs/DN & then any recommendations are then approved at the APC.

5. Please provide information on who is responsible for the cost of wound care in your setting – is it CCG or Acute?

In the hospital, the acute Trust is responsible for the costs. Where the Trust community services team support the district nursing services, then the CCG is responsible for these costs.

6. Please provide information if the wound care products is on prescription FP10?

Not applicable. There should be few FP10 prescriptions issued by the Trust.  Only those required urgently should be prescribed form the outpatient clinics. Dressings which are required urgently should be those included in the formulary.

7. Please provide a list of the wound care products that you are planning to keep on prescription FP10?

Not applicable, as above

8. Please provide information if you are planning to take wound care products off prescription FP10?

Only those dressings required urgently should be prescribed. There are no immediate plans to bar all dressings prescribing from FP10s. FP10s are used exceptionally. Most outpatients prescribing is undertaken on hospital outpatient prescriptions.

9. Please provide a list of the wound care products that you are planning to take off prescription FP10?

Not applicable

10. Do you hold information about your patient demographic? If so, please provide information on what is your patient demographic?

We capture the following information on our Trust MPI ( Master Patient Index)

• Name
• Address
• Date of Birth
• GP
• Ethnicity
• Religion
• NHS Number
• Telephone contact details

11. What are the most commonly treated wounds from your patient demographic?

Pressure ulcers, chronic leg ulcers, diabetic foot ulcers, surgical wounds

 

12. Please provide any information that you have relating to the average monthly usage of each product in the formulary?

Please see Note 1 below.

13. Please provide information on the number of wound care products used that are not currently on the formulary?

Approximately 210 brands not on formulary

14. Please provide any information on the monthly usage levels for non-formulary wound care products in the last twelve months?

158,000 individual products packs / singles in an average month

15. How often do you review your wound care formulary and when was this last undertaken?

A significant review of the wound care formulary was undertaken by the Birmingham, Solihull and environs Area Prescribing Committee in Q4 16/17. A copy of the formulary will be available on that website.

The Trust formulary will be smaller, comprising a smaller selection of the dressings. We have on-going review of the products on our formulary, adjusting as required

16. Please provide information about the procedure that you use of the information you assess when reviewing your formulary?

See question 4

17. Please provide a list of the suppliers that are currently on your formulary?

SMITH AND NEPHEW, ADVANCIS, CLINIMED, CONVATEC, HARTMANN, ASPEN, SYSTAGENIX, 3M, ARIA MEDICAL, URGO, H & R HEALTHCARE, CLINI SUPPLIES, ROCIALLE, SHERMOND, CRAWFORD, MOLNLYCKE, MOLNLYCKE.

18. Please provide figures for your total spend on wound care products in 2015 and 2016?

Please see Note 1 below.

19. Please provide figures for your total spend on Compression bandages in 2015 and 2016?

Please see Note 1 below.

20. Please provide figures for your total spend on Foam dressings in 2015 and 2016?

Please see Note 1 below.

21. Please provide figures for your total spend on Anti-Microbial wound care products in 2015 and 2016?

Please see Note 1 below.

22. Please provide figures for your total spend on Alginate (Silver) wound care products in 2015 and 2016?

Please see Note 1 below.

23. Please provide figures for your total spend on Hydrocolloid wound care products in 2015 and 2016?

Please see Note 1 below.

24. Please provide figures for your total spend on Wound contact products in 2015 and 2016?

Please see Note 1 below.

25. Please provide figures for your total spend on Exudate Absorber (Super Absorber) Dressings products in 2015 and 2016?

Please see Note 1 below.

26. Please provide figures for your total spend on Acute Wound Care products – Post Op Film Dressing Plus Pads, Steri-Strips, Stockinette and Semi Permeable Film Dressings in 2015 and 2016?

Please see Note 1 below.

27. Please provide figures for your total spend on Skin Integrity wound products – Barrier Films and Barrier Creams in 2015 and 2016?

Please see Note 1 below.

28. Please provide figures for your total spend on Vascular Access wound products – Semi Permeable Film Dressings and IV Dressings in 2015 and 2016?

Please see Note 1 below.

29. Please provide figures for your total spend on hosiery products in 2015 and 2016?

Please see Note 1 below.

30. Are you planning on collaborating with another healthcare entity to provide wound care services?

Pharmacy will purchase their dressings from nationally agreed suppliers where applicable.  If appropriate, there are systems in place to collaborate with purchasing hubs.

31. Please provide information on your current supply route – DHL, wholesaler or vendor direct?

Pharmacy purchase via the recommended route from national contracts.

32. Do you currently have a contract in place for supply of wound care products? If so when does it expire?

Pharmacy will purchase their dressings from nationally agreed suppliers where applicable.  If appropriate, there are systems in place to collaborate with purchasing hubs.

33. Please provide information on how many delivery points do you have for wound care deliveries?

There are three delivery points.  One on each hospital site.

34. Please provide information on how many community locations are holding stock of wound care and prescribing to the community?

Community services have 4 storage areas

35. Please provide information on what software platform do you use for ordering wound care products?

JAC Pharmacy Medicines Management system.

iProc  orders via NHS Supply Chain and direct with suppliers

36. Do you have a wound care clinic in place for your local demographic and where do your referrals come from?

No. however we do provide for inpatients.

Note 1: The Trust does hold this information. However we are withholding this under exemption 43 (commercial interests) of the Freedom of Information Act: The Information is exempt information if its disclosure under this Act would, or would be likely to, prejudice the commercial interests of any person (including the public authority holding it) as the Trust will be retendering for this product and it is believed that releasing this could disadvantage the trust in future negotiations.  In considering this, we have taken into account the public interest test and it is believed the public interest in securing the best possible price outweighs the public interest in releasing this at this time.”